Publication: FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS.
| dc.contributor.author | Amo, Gemma | |
| dc.contributor.author | Cornejo-García, José A | |
| dc.contributor.author | García-Menaya, Jesus M | |
| dc.contributor.author | Cordobes, Concepcion | |
| dc.contributor.author | Torres, M J | |
| dc.contributor.author | Esguevillas, Gara | |
| dc.contributor.author | Mayorga, Cristobalina | |
| dc.contributor.author | Martinez, Carmen | |
| dc.contributor.author | Blanca-Lopez, Natalia | |
| dc.contributor.author | Canto, Gabriela | |
| dc.contributor.author | Ramos, Alfonso | |
| dc.contributor.author | Blanca, Miguel | |
| dc.contributor.author | Agúndez, José A G | |
| dc.contributor.author | García-Martín, Elena | |
| dc.contributor.authoraffiliation | [Amo,G; Esguevillas,G; Martínez,C; Agúndez,JAG; García-Martín,E] Departamento de Farmacología, Universidad de Extremadura, Cáceres, Spain. [Cornejo,JA; Mayorga,C] Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [García-Menaya,JM; Cordobes,C] Servicio de Alergologia, Hospital Infanta Cristina, Badajoz, Spain. [Torres,MJ] UGC de Alergia, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [Blanca-Lopez,N; Canto,G; Blanca,M] Servicio de Alergologia, Hospital Infanta Leonor, Madrid, Spain. [Ramos,A] Departamento de Matemáticas, Universidad de Extremadura, Cáceres, Spain. | |
| dc.date.accessioned | 2024-01-16T12:16:34Z | |
| dc.date.available | 2024-01-16T12:16:34Z | |
| dc.date.issued | 2016-09-29 | |
| dc.description.abstract | The high-affinity IgE receptor (Fcε RI) is a heterotetramer of three subunits: Fcε RIα, Fcε RIβ, and Fcε RIγ (αβγ2) encoded by three genes designated as FCER1A, FCER1B (MS4A2), and FCER1G, respectively. Recent evidence points to FCERI gene variability as a relevant factor in the risk of developing allergic diseases. Because Fcε RI plays a key role in the events downstream of the triggering factors in immunological response, we hypothesized that FCERI gene variants might be related with the risk of, or with the clinical response to, selective (IgE mediated) non-steroidal anti-inflammatory (NSAID) hypersensitivity. From a cohort of 314 patients suffering from selective hypersensitivity to metamizole, ibuprofen, diclofenac, paracetamol, acetylsalicylic acid (ASA), propifenazone, naproxen, ketoprofen, dexketoprofen, etofenamate, aceclofenac, etoricoxib, dexibuprofen, indomethacin, oxyphenylbutazone, or piroxicam, and 585 unrelated healthy controls that tolerated these NSAIDs, we analyzed the putative effects of the FCERI SNPs FCER1A rs2494262, rs2427837, and rs2251746; FCER1B rs1441586, rs569108, and rs512555; FCER1G rs11587213, rs2070901, and rs11421. Furthermore, in order to identify additional genetic markers which might be associated with the risk of developing selective NSAID hypersensitivity, or which may modify the putative association of FCERI gene variations with risk, we analyzed polymorphisms known to affect histamine synthesis or metabolism, such as rs17740607, rs2073440, rs1801105, rs2052129, rs10156191, rs1049742, and rs1049793 in the HDC, HNMT, and DAO genes. No major genetic associations with risk or with clinical presentation, and no gene-gene interactions, or gene-phenotype interactions (including age, gender, IgE concentration, antecedents of atopy, culprit drug, or clinical presentation) were identified in patients. However, logistic regression analyses indicated that the presence of antecedents of atopy and the DAO SNP rs2052129 (GG) were strongly related (P < 0.001 and P = 0.005, respectively) with selective hypersensitivity to ibuprofen. With regard to patients with selective hypersensitivity to ASA, men were more prone to develop such a reaction than women (P = 0.011), and the detrimental DAO SNP rs10156191 in homozygosity increased the risk of developing such hypersensitivity (P = 0.039). | |
| dc.description.sponsorship | This study was financed by grants PI12/00241, PI12/00324, PI15/00303, RETICS RD12/0013/0002, and RETICS RD16/0006/0004 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain, and GR15026 from Junta de Extremadura, Spain. Financed in part with FEDER funds from the European Union. | |
| dc.identifier.doi | 10.3389/fphar.2016.00353 | |
| dc.identifier.e-issn | 1663-9812 | es_ES |
| dc.identifier.journal | Frontiers in Pharmacology | es_ES |
| dc.identifier.other | http://hdl.handle.net/10668/2511 | |
| dc.identifier.pubmedID | 27746735 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/17159 | |
| dc.language.iso | eng | |
| dc.publisher | Frontiers Media | |
| dc.relation.publisherversion | http://journal.frontiersin.org/article/10.3389/fphar.2016.00353/full#h1 | es |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Attribution 4.0 International | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | Fcε | |
| dc.subject | RI | |
| dc.subject | Histamine | |
| dc.subject | Non-steroidal anti-inflammatory drugs (NSAIDS) | |
| dc.subject | Hypersensitivity drug reactions | |
| dc.subject | Biomarkers | |
| dc.subject | Acetaminofén | |
| dc.subject | Antiinflamatorios no Esteroideos | |
| dc.subject | Aspirina | |
| dc.subject | Diclofenaco | |
| dc.subject | Dipirona | |
| dc.subject | Ácido flufenámico | |
| dc.subject | Marcadores genéticos | |
| dc.subject | Histamina | |
| dc.subject | Ibuprofeno | |
| dc.subject | Inmunoglobulina E | |
| dc.subject | Indometacina | |
| dc.subject | Cetoprofeno | |
| dc.subject | Modelos logísticos | |
| dc.subject | Naproxeno | |
| dc.subject | Oxifenilbutazona | |
| dc.subject | Piroxicam | |
| dc.subject | Polimorfismo de Nucleótido Simple | |
| dc.subject | Piridinas | |
| dc.subject | Receptores de IgE | |
| dc.subject | Sulfonas | |
| dc.subject.mesh | Acetaminophen | |
| dc.subject.mesh | Anti-Inflammatory Agents, Non-Steroidal | |
| dc.subject.mesh | Aspirin | |
| dc.subject.mesh | Diclofenac | |
| dc.subject.mesh | Dipyrone | |
| dc.subject.mesh | Flufenamic Acid | |
| dc.subject.mesh | Genetic Markers | |
| dc.subject.mesh | Histamine | |
| dc.subject.mesh | Ibuprofen | |
| dc.subject.mesh | Immunoglobulin E | |
| dc.subject.mesh | Indomethacin | |
| dc.subject.mesh | Ketoprofen | |
| dc.subject.mesh | Logistic Models | |
| dc.subject.mesh | Naproxen | |
| dc.subject.mesh | Oxyphenbutazone | |
| dc.subject.mesh | Piroxicam | |
| dc.subject.mesh | Polymorphism, Single Nucleotide | |
| dc.subject.mesh | Pyridines | |
| dc.subject.mesh | Receptors, IgE | |
| dc.subject.mesh | Sulfur Compounds | |
| dc.title | FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isPublisherOfPublication | 9f9fa5ea-093b-43d8-bf2c-5bd65d08a802 | |
| relation.isPublisherOfPublication.latestForDiscovery | 9f9fa5ea-093b-43d8-bf2c-5bd65d08a802 |


